CDK4 and neoplasm: In this study, we found that the combination of CDK4/6 inhibitor SHR6390 and pan-her inhibitor pyrotinib in HER2+/HR+ cell lines (EFM-192A and BT474) shows synergistic inhibition of tumor proliferation and enhances antitumor effects in vitro.